Welcome to our dedicated page for Pliant Therapeutics SEC filings (Ticker: PLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pliant Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing integrin-based therapeutics. Recent 8-K reports cover quarterly financial results, corporate updates for the PLN-101095 oncology program, material agreements, at-the-market equity offering arrangements, and amendments to the company’s stockholder rights agreement and Series A Junior Participating Preferred Purchase Rights.
Proxy and governance filings describe board composition, director retirements, committee roles, executive compensation, equity awards, and stockholder voting matters. Other material-event reports record officer appointments or departures and changes affecting security-holder rights, connecting the company’s capital structure and governance disclosures to its clinical-stage operating model.
Pliant Therapeutics reported a much smaller net loss of $20.0 million for the quarter ended March 31, 2026, compared with $56.2 million a year earlier, as it completed restructuring and shifted focus to oncology. Operating expenses fell sharply, with research and development down to $13.6 million and general and administrative to $8.2 million.
The company ended the quarter with $172.4 million in cash, cash equivalents, restricted cash and short-term investments and no outstanding debt, and believes this will fund operations for at least the next 12 months and beyond. Pliant is now centered on its integrin-based solid tumor program, PLN‑101095, with a Phase 1b FORTIFY trial enrolling and updated Phase 1 data showing anti-tumor activity in combination with pembrolizumab.
Pliant Therapeutics reported first quarter 2026 results and highlighted progress in its oncology and delivery platforms. The company’s lead program, PLN-101095, advanced with first patient dosed in FORTIFY, a Phase 1b indication expansion trial in checkpoint inhibitor-refractory solid tumors, with interim data expected in 2027.
Updated Phase 1 data for PLN-101095 presented at AACR 2026 showed one confirmed complete response, two confirmed partial responses and one unconfirmed partial response in heavily pretreated patients, with biomarker changes consistent with enhanced immune activity and a generally well tolerated safety profile. Pliant is also advancing an integrin-targeted delivery platform for tissue-specific siRNA delivery.
Financially, first quarter 2026 research and development expenses were $13.6 million and general and administrative expenses were $8.2 million, both sharply lower than the prior-year period. Net loss narrowed to $20.0 million, or $0.32 per share, and the company ended March 31, 2026 with $172.4 million in cash, cash equivalents and short-term investments, which it expects to fund operations into the second half of 2028.
Pliant Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders as a virtual-only event on June 11, 2026 at 8:30 a.m. Pacific Time. Stockholders of record as of April 15, 2026, when 61,914,664 common shares were outstanding, may vote online, by phone, or by mail.
Stockholders will vote on electing three Class III directors for terms running to the 2029 meeting, approving on an advisory basis 2025 compensation for named executive officers, and ratifying Deloitte & Touche LLP as independent registered public accounting firm for 2026. The board also outlines committee structures, director independence, compensation policies, and a pay‑for‑performance executive compensation framework emphasizing variable and equity-based incentives.
Pliant Therapeutics, Inc. Chief Operating Officer Minnie Kuo reported an option repricing affecting her existing stock options. On the April 17, 2026 effective date, she surrendered options covering 150,000, 40,000 and 55,200 shares of common stock with exercise prices of $16.18, $17.44 and $11.14, respectively, and received new options for the same share amounts at an exercise price of $1.33 per share.
The board approved this company‑wide repricing on April 15, 2026 for options granted on or before March 1, 2025, and all other terms, including vesting under the 2020 and 2022 plans, remain unchanged. The repriced awards may revert to their original exercise prices if exercised during an eighteen‑month “Retention Period” starting on the effective date, or if Kuo is terminated for cause or resigns (other than for good reason) before that period ends, subject to the detailed conditions described.
PLIANT THERAPEUTICS, INC. Chief Financial Officer Keith Lamont Cummings reported an option repricing approved by the board on April 17, 2026. Existing stock options granted on or before March 1, 2025 were cancelled and replaced, share-for-share, with new options at an exercise price of $1.33 per share.
The repriced options keep their original vesting schedules and updated expiration dates as previously reported. During a defined Retention Period starting April 17, 2026, any repriced option exercised will revert to its original higher exercise price, and the options can also revert if certain termination or resignation conditions occur.
Pliant Therapeutics President and CEO Bernard Coulie reported an option repricing affecting several existing stock option grants. On the April 17, 2026 effective date, multiple options covering common stock were surrendered to the issuer and regranted with a new exercise price of $1.33 per share, replacing higher original exercise prices such as $34.65 and $26.50. The board approved this repricing for options granted on or before March 1, 2025, with all other terms unchanged.
The repriced options will revert to their original exercise prices if exercised during an eighteen‑month Retention Period starting April 17, 2026, or upon certain termination or resignation events described in the CEO’s severance plan. Several option expiration dates were also corrected, including updates to January 24, 2029 and March 31, 2030.
PLIANT THERAPEUTICS, INC. granted its Chief Human Resource Officer, Lily Cheung, a series of repriced stock options as part of a board-approved option repricing effective April 17, 2026. Existing options covering 123,000, 52,000 and 51,750 shares of common stock, previously struck at $21.935, $17.44 and $11.14 per share, were surrendered back to the company and replaced with new options over the same share amounts at an exercise price of $1.33 per share, the closing price on the effective date.
All other terms of the options, including vesting under the company’s 2020 Stock Option and Incentive Plan, remain unchanged. The repriced options can revert to their original exercise prices if exercised during a defined Retention Period or if Cheung’s employment ends under certain conditions, and a prior expiration date has been corrected to January 19, 2033.
Pliant Therapeutics, Inc. announced that three directors — David E.I. Pyott, Katharine Knobil, M.D., and Suzanne Bruhn, Ph.D. — will retire from the Board and all committees effective at the 2026 Annual Meeting, with each stating the decision was not due to any disagreement with the company.
The Board also approved an option repricing effective April 17, 2026, resetting all employee stock options granted on or before March 1, 2025 under its equity plans to an exercise price of $1.33 per share, the closing market price on the Effective Date. To benefit from the new price, employees must remain in service through a defined Retention Period — 18 months for the executive leadership team and 12 months for other employees — subject to specified exceptions such as certain corporate transactions, qualifying terminations, death or disability. If an employee is terminated for cause, resigns early without good reason (for vice presidents and above), or exercises options before the Retention Period ends, the options revert to their original higher exercise price. The company states the repricing is intended to retain and motivate employees, including executive officers, without additional equity dilution or cash compensation.